MA26680A1 - Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number: MA26680A1
Authority: MA; Morocco
Prior art keywords: alcynyl; quinolein; substitute; derivatives; preparation
Prior art date: 1998-08-27

Application number

MA25743A

Other languages

English (en)

Inventor

Deborah La Greca Susan

Peter Lyssikatos Joseph

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-25

Publication date

2004-12-20

1999-08-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA26680A1 publication Critical patent/MA26680A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA25743A 1998-08-27 1999-08-25 Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant MA26680A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9814598P	1998-08-27	1998-08-27

Publications (1)

Publication Number	Publication Date
MA26680A1 true MA26680A1 (fr)	2004-12-20

Family

ID=22267481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA25743A MA26680A1 (fr)	1998-08-27	1999-08-25	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (40)

Country	Link
US (3)	US6150377A (fr)
EP (1)	EP1107963B1 (fr)
JP (1)	JP3495706B2 (fr)
KR (1)	KR20010072991A (fr)
CN (1)	CN1314904A (fr)
AP (1)	AP2001002079A0 (fr)
AT (1)	ATE321037T1 (fr)
AU (1)	AU4925499A (fr)
BG (1)	BG105365A (fr)
BR (1)	BRPI9913138B8 (fr)
CA (2)	CA2341690C (fr)
CO (1)	CO5130017A1 (fr)
CZ (1)	CZ2001660A3 (fr)
DE (1)	DE69930518T2 (fr)
DZ (1)	DZ2880A1 (fr)
EA (1)	EA200100135A1 (fr)
EE (1)	EE200100118A (fr)
ES (1)	ES2259237T3 (fr)
GE (1)	GEP20033001B (fr)
GT (1)	GT199900140A (fr)
HK (1)	HK1039123A1 (fr)
HR (1)	HRP20010142A2 (fr)
HU (1)	HUP0103228A3 (fr)
ID (1)	ID27562A (fr)
IL (1)	IL141239A0 (fr)
IS (1)	IS5818A (fr)
MA (1)	MA26680A1 (fr)
NO (1)	NO20010964L (fr)
NZ (1)	NZ509372A (fr)
OA (1)	OA11645A (fr)
PA (1)	PA8480101A1 (fr)
PE (1)	PE20000986A1 (fr)
PL (1)	PL346426A1 (fr)
SK (1)	SK2442001A3 (fr)
SV (1)	SV1999000141A (fr)
TN (1)	TNSN99162A1 (fr)
TR (1)	TR200101343T2 (fr)
UY (1)	UY25682A1 (fr)
WO (1)	WO2000012499A1 (fr)
ZA (1)	ZA200101173B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
EP1107962B1 (fr) *	1998-08-27	2005-02-23	Pfizer Products Inc.	Derives de quinolin-2-one utiles en tant qu'agents anticancereux
JP3495706B2 (ja) *	1998-08-27	2004-02-09	ファイザー・プロダクツ・インク	抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
BR0008202A (pt)	1999-02-11	2002-02-19	Pfizer Prod Inc	Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (fr)	2000-02-24	2007-10-17	Janssen Pharmaceutica N.V.	Regime posologique contenante inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer
JO2361B1 (en) *	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024686A2 (fr) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase
US7067531B2 (en)	2000-09-25	2006-06-27	Angibaud Patrick Rene	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002024682A1 (fr)	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de quinoline et de quinazoline inhibant la farnesyl transferase comme inhibiteurs de farnesyl transferase
US7173040B2 (en)	2000-09-25	2007-02-06	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7153958B2 (en)	2000-11-21	2006-12-26	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting benzoheterocyclic derivatives
BR0116302A (pt)	2000-12-19	2004-01-13	Pfizer Prod Inc	Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
EP1347966B1 (fr)	2000-12-27	2006-03-08	Janssen Pharmaceutica N.V.	Quinoline 4-substituee inhibitrice de la transferase farnesyl et derives de quinazoline
WO2002056884A2 (fr) *	2001-01-22	2002-07-25	Schering Corporation	Traitement du paludisme au moyen d'inhibiteurs de la farnesyl proteine transferase (fpt)
BRPI0208075B8 (pt) *	2001-03-12	2021-05-25	Janssen Pharmaceutica Nv	processo para a preparação de compostos de imidazol
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
WO2002080895A2 (fr) *	2001-04-06	2002-10-17	Schering Corporation	Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
WO2002098425A1 (fr) *	2001-06-04	2002-12-12	Cytovia, Inc.	Quinolinones 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)- substituees, et analogues utilises comme activateurs de caspases et inducteurs d'apoptose, et utilisation y relative
US6713462B2 (en)	2001-06-21	2004-03-30	Ariad Pharmaceuticals, Inc.	Quinolinones and uses thereof
US6740757B2 (en) *	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
AU2002358677B2 (en)	2001-12-19	2008-02-07	Janssen Pharmaceutica N.V.	1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (fr)	2002-03-22	2007-06-13	Janssen Pharmaceutica N.V.	Derives de 2-quinoleine et de 2-quinazoline substitues par du benzylimidazole utilises en tant qu'inhibiteurs de farnesyl transferase
CA2481480C (fr)	2002-04-15	2011-04-12	Janssen Pharmaceutica N.V.	Derives de quinazoline tricylique inhibant la farnesyl transferase substitues avec des imidazoles ou des triazoles a liaison carbone
BR0317548A (pt) *	2002-12-19	2005-11-22	Pfizer	Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
CA2546727C (fr)	2003-11-20	2012-10-02	Children's Hospital Medical Center	Inhibiteurs de gtpase et procedes d'utilisation correspondants
US20050272722A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
CA2561516A1 (fr) *	2004-03-30	2005-10-13	Pfizer Products Inc.	Combinaisons d'inhibiteurs de transduction de signaux
MX2007001986A (es) *	2004-08-26	2007-05-10	Pfizer	Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
ATE492544T1 (de) *	2004-08-26	2011-01-15	Pfizer	Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
BRPI0513915A (pt)	2004-08-26	2008-05-20	Pfizer	compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
PL1815247T3 (pl)	2004-11-05	2013-08-30	Janssen Pharmaceutica Nv	Terapeutyczne zastosowanie inhibitorów transferazy farnezylowej i metody kontroli ich skuteczności
US20060107555A1 (en) *	2004-11-09	2006-05-25	Curtis Marc D	Universal snow plow adapter
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP1920048A4 (fr)	2005-07-29	2009-12-09	Childrens Hosp Medical Center	Inhibiteurs de gtpase et méthodes d'utilisation et structure cristalline de la gtpase rac-1
MY164457A (en)	2005-09-07	2017-12-15	Amgen Fremont Inc	Human monoclonal antibodies to activin receptor-like kinase-1
ATE533057T1 (de)	2005-09-20	2011-11-15	Osi Pharm Inc	Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20070213366A1 (en)	2005-12-23	2007-09-13	Justman Craig J	Treatment of Synucleinopathies
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2016070B1 (fr)	2006-04-20	2016-01-13	Janssen Pharmaceutica N.V.	Inhibiteurs de la c-fms kinase
US7414050B2 (en)	2006-04-20	2008-08-19	Janssen Pharmaceutica, N.V.	Inhibitors of c-fms kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
EP2258700A1 (fr)	2006-05-09	2010-12-08	Pfizer Products Inc.	Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
EP2056874B1 (fr)	2006-08-21	2012-09-19	F. Hoffmann-La Roche AG	Thérapie tumorale avec anticorps anti-vegf
US20100184803A1 (en) *	2007-03-09	2010-07-22	Link Medicine Corporation	Treatment of Lysosomal Storage Diseases
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
WO2009151683A2 (fr)	2008-03-12	2009-12-17	Link Medicine Corporation	Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en)	2008-11-13	2010-05-20	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2400985A2 (fr)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Thérapie anti-cancer combinée
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099364A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
AU2011223655A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (fr)	2010-03-03	2012-11-07	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
US20120214830A1 (en)	2011-02-22	2012-08-23	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
WO2013166043A1 (fr)	2012-05-02	2013-11-07	Children's Hospital Medical Center	Rajeunissement de cellules précurseurs
JOP20180012A1 (ar)	2012-08-07	2019-01-30	Janssen Pharmaceutica Nv	عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9303046B2 (en)	2012-08-07	2016-04-05	Janssen Pharmaceutica Nv	Process for the preparation of heterocyclic ester derivatives
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
HUE049620T2 (hu)	2015-08-17	2020-09-28	Kura Oncology Inc	Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
JP6877429B2 (ja)	2015-12-03	2021-05-26	アジオスファーマシューティカルズ，インコーポレイテッド	Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
WO2017184968A1 (fr)	2016-04-22	2017-10-26	Kura Oncology, Inc.	Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
PT3534885T (pt)	2016-11-03	2021-04-13	Kura Oncology Inc	Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro
EP3579872A1 (fr)	2017-02-10	2019-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
US10137121B2 (en)	2017-02-21	2018-11-27	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
EP3432883B1 (fr)	2017-02-21	2021-07-28	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
EP3664804A4 (fr)	2017-08-07	2021-04-14	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
KR20210098969A (ko)	2018-11-01	2021-08-11	쿠라 온콜로지, 인크.	파네실트랜스퍼라제 저해제를 사용한 암의 치료 방법
EP3897638A1 (fr)	2018-12-21	2021-10-27	Kura Oncology, Inc.	Procédé de traitement de carcinomes à cellules squameuses
WO2020180663A1 (fr)	2019-03-01	2020-09-10	Kura Oncology, Inc.	Méthodes de traitement du cancer à l'aide d'inhibiteurs de farnésyltransférase
TW202108170A (zh)	2019-03-15	2021-03-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
CA3134825A1 (fr)	2019-03-29	2020-10-08	Kura Oncology, Inc.	Procedes de traitement de carcinomes squameux par des inhibiteurs de farnesyltransferase
WO2020205387A1 (fr)	2019-04-01	2020-10-08	Kura Oncology, Inc.	Méthodes de traitement du cancer à l'aide d'inhibiteurs de la farnésyltransférase
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2020223583A1 (fr)	2019-05-02	2020-11-05	Kura Oncology, Inc.	Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
JP7718659B2 (ja)	2019-08-16	2025-08-05	チルドレンズホスピタルメディカルセンター	Ｃｄｃ４２特異的阻害剤で対象を治療する方法
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
ATE321757T1 (de) *	1995-12-08	2006-04-15	Janssen Pharmaceutica Nv	(imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
JP3495706B2 (ja) *	1998-08-27	2004-02-09	ファイザー・プロダクツ・インク	抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体

1999
- 1999-08-06 JP JP2000567527A patent/JP3495706B2/ja not_active Expired - Fee Related
- 1999-08-06 AT AT99933084T patent/ATE321037T1/de not_active IP Right Cessation
- 1999-08-06 PL PL99346426A patent/PL346426A1/xx not_active Application Discontinuation
- 1999-08-06 CA CA002341690A patent/CA2341690C/fr not_active Expired - Fee Related
- 1999-08-06 HK HK02100579.7A patent/HK1039123A1/zh unknown
- 1999-08-06 ID IDW20010457A patent/ID27562A/id unknown
- 1999-08-06 OA OA1200100051A patent/OA11645A/en unknown
- 1999-08-06 EE EEP200100118A patent/EE200100118A/xx unknown
- 1999-08-06 CN CN99810204A patent/CN1314904A/zh active Pending
- 1999-08-06 AP APAP/P/2001/002079A patent/AP2001002079A0/en unknown
- 1999-08-06 HR HR20010142A patent/HRP20010142A2/hr not_active Application Discontinuation
- 1999-08-06 HU HU0103228A patent/HUP0103228A3/hu unknown
- 1999-08-06 BR BRPI9913138A patent/BRPI9913138B8/pt not_active IP Right Cessation
- 1999-08-06 ES ES99933084T patent/ES2259237T3/es not_active Expired - Lifetime
- 1999-08-06 EA EA200100135A patent/EA200100135A1/ru unknown
- 1999-08-06 IL IL14123999A patent/IL141239A0/xx unknown
- 1999-08-06 WO PCT/IB1999/001398 patent/WO2000012499A1/fr not_active Ceased
- 1999-08-06 DE DE69930518T patent/DE69930518T2/de not_active Expired - Lifetime
- 1999-08-06 EP EP99933084A patent/EP1107963B1/fr not_active Expired - Lifetime
- 1999-08-06 CA CA002578326A patent/CA2578326C/fr not_active Expired - Fee Related
- 1999-08-06 SK SK244-2001A patent/SK2442001A3/sk unknown
- 1999-08-06 CZ CZ2001660A patent/CZ2001660A3/cs unknown
- 1999-08-06 TR TR2001/01343T patent/TR200101343T2/xx unknown
- 1999-08-06 GE GEAP19995770A patent/GEP20033001B/en unknown
- 1999-08-06 KR KR1020017002442A patent/KR20010072991A/ko not_active Ceased
- 1999-08-06 NZ NZ509372A patent/NZ509372A/en unknown
- 1999-08-06 AU AU49254/99A patent/AU4925499A/en not_active Abandoned
- 1999-08-10 PA PA19998480101A patent/PA8480101A1/es unknown
- 1999-08-24 GT GT199900140A patent/GT199900140A/es unknown
- 1999-08-25 DZ DZ990180A patent/DZ2880A1/fr active
- 1999-08-25 TN TNTNSN99162A patent/TNSN99162A1/fr unknown
- 1999-08-25 MA MA25743A patent/MA26680A1/fr unknown
- 1999-08-26 US US09/383,755 patent/US6150377A/en not_active Expired - Lifetime
- 1999-08-26 PE PE1999000862A patent/PE20000986A1/es not_active Application Discontinuation
- 1999-08-27 CO CO99054519A patent/CO5130017A1/es unknown
- 1999-08-27 UY UY25682A patent/UY25682A1/es unknown
- 1999-08-27 SV SV1999000141A patent/SV1999000141A/es not_active Application Discontinuation
2000
- 2000-07-27 US US09/628,039 patent/US6294552B1/en not_active Expired - Lifetime
2001
- 2001-01-19 IS IS5818A patent/IS5818A/is unknown
- 2001-02-12 ZA ZA200101173A patent/ZA200101173B/en unknown
- 2001-02-26 NO NO20010964A patent/NO20010964L/no not_active Application Discontinuation
- 2001-03-20 BG BG105365A patent/BG105365A/xx unknown
- 2001-07-06 US US09/900,401 patent/US6579887B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
UY25682A1 (es)	2000-03-31
GEP20033001B (en)	2003-06-25
DZ2880A1 (fr)	2003-12-15
EP1107963A1 (fr)	2001-06-20
NO20010964D0 (no)	2001-02-26
EA200100135A1 (ru)	2001-08-27
EP1107963B1 (fr)	2006-03-22
EE200100118A (et)	2002-06-17
PA8480101A1 (es)	2003-06-30
DE69930518T2 (de)	2006-09-21
BG105365A (en)	2001-11-30
NO20010964L (no)	2001-04-26
ES2259237T3 (es)	2006-09-16
CO5130017A1 (es)	2002-02-27
JP3495706B2 (ja)	2004-02-09
CZ2001660A3 (cs)	2002-05-15
PE20000986A1 (es)	2000-09-30
IS5818A (is)	2001-01-19
US6579887B2 (en)	2003-06-17
ATE321037T1 (de)	2006-04-15
HK1039123A1 (zh)	2002-04-12
TR200101343T2 (tr)	2001-09-21
JP2002523504A (ja)	2002-07-30
SV1999000141A (es)	2000-07-06
CA2341690A1 (fr)	2000-03-09
AP2001002079A0 (en)	2001-03-31
BR9913138B1 (pt)	2013-11-05
US20020128287A1 (en)	2002-09-12
HUP0103228A2 (hu)	2002-02-28
AU4925499A (en)	2000-03-21
US6150377A (en)	2000-11-21
PL346426A1 (en)	2002-02-11
SK2442001A3 (en)	2002-10-08
BRPI9913138B8 (pt)	2016-05-17
ID27562A (id)	2001-04-12
ZA200101173B (en)	2002-04-12
GT199900140A (es)	2001-02-14
HUP0103228A3 (en)	2003-01-28
CA2341690C (fr)	2007-04-17
CA2578326C (fr)	2009-11-24
TNSN99162A1 (fr)	2005-11-10
WO2000012499A1 (fr)	2000-03-09
US6294552B1 (en)	2001-09-25
OA11645A (en)	2004-11-16
CN1314904A (zh)	2001-09-26
IL141239A0 (en)	2002-03-10
BR9913138A (pt)	2001-05-08
DE69930518D1 (de)	2006-05-11
NZ509372A (en)	2003-08-29
HRP20010142A2 (en)	2002-02-28
KR20010072991A (ko)	2001-07-31
CA2578326A1 (fr)	2000-03-09

Publication	Publication Date	Title
MA26680A1 (fr)	2004-12-20	Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26638A1 (fr)	2004-12-20	Derives d'isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26479A1 (fr)	2004-12-20	Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26465A1 (fr)	2004-12-20	Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26624A1 (fr)	2004-12-20	Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr)	2004-12-20	Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2740136B1 (fr)	1998-01-09	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26468A1 (fr)	2004-12-20	Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26740A1 (fr)	2004-12-20	Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26425A1 (fr)	2004-12-20	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26505A1 (fr)	2004-12-20	Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26614A1 (fr)	2004-12-20	Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26414A1 (fr)	2004-12-20	Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
FR2794742B1 (fr)	2005-06-03	Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2735777B1 (fr)	1997-09-12	Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .